LAIV

(redirected from Live Attenuated Influenza Vaccine)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to Live Attenuated Influenza Vaccine: FluMist
AcronymDefinition
LAIVLive Attenuated Influenza Vaccine
LAIVLow Adult Immunity to Varicella
References in periodicals archive ?
Naykhin et al., "H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial," The Lancet Infectious Diseases, vol.
Live Attenuated Influenza Vaccine is sold as FluMist Quadrivalent and is produced by AstraZeneca subsidiary, MedImmune.
* The nasal-spray is a Live Attenuated Influenza Vaccine (LAIV).
would deliver approximately 3 million doses of Flu-Mist, the live attenuated influenza vaccine (MMWR 2005; 54:850).
There are also approximately 3 million doses of LAIV (live attenuated influenza vaccine) available in the United States this season, which are administered nasally for those aged 5-49.
Clinicians should remind healthy patients aged 5-49 years of the availability of live attenuated influenza vaccine, called FluMist.
Specifically as for children aged 2-17 years old, the risk of influenza was not significantly lower among those who received the quadrivalent live attenuated influenza vaccine than among those who received no vaccine; the inactivated vaccine had a marked benefit over no vaccine (vaccine effectiveness, 60%; 95% CI, 47-70; P less than .001).
Because of its low effectiveness against influenza A(H1N1)pdm09 in the United States during the 2013-14 and 2015-16 seasons, ACIP made the interim recommendation that quadrivalent live attenuated influenza vaccine should not be used for the 2016-17 season (2).
The Advisory Committee on Immunization Practices (ACIP) took the unusual step at its June 2016 meeting of recommending against using a currendy licensed vaccine, live attenuated influenza vaccine (LAIV), in the 2016-2017 influenza season.
At the June 2016 CDC's Advisory Committee on Immunization Practices (ACIP) meeting, data were presented comparing the efficacy of this season's live attenuated influenza vaccine (LAIV) with inactivated influenza vaccine (IIV) by age and specific influenza type and subtype.
M2 PHARMA-June 24, 2016-US Centers for Disease Control and Prevention recommends against live attenuated influenza vaccine
AstraZeneca today confirmed that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has provided its interim recommendation on the use of FluMist Quadrivalent Live Attenuated Influenza Vaccine (FluMist Quadrivalent) in the US for the 2016-2017 influenza season.